Another 215 layoffs linked to Novo's New Jersey HQ

Conceptual illustration of layoffs featuring rows of translucent human figures overlaid with large blue scissors, symbolizing
Restructuring has been a key component of new CEO Mike Doustdar’s attempt to right the ship since he took the reins of the company in mid-2025. (Image concept and design by Ayla Ellison. Source images licensed from Getty Images.)

Novo is adding to its 2027 layoff count. In February of next year more than 200 employees who report to the company’s Plainsboro headquarters in New Jersey will be parting ways with the Danish drugmaker. 

In a filing registered with the New Jersey labor department, Novo disclosed 215 job cuts linked to the Plainsboro HQ slated to take effect between Feb. 17 and Feb. 19. News of the February cuts comes on the heels of a 108-person layoff already scheduled for the year’s end. 

When questioned by Fierce, Novo declined to elaborate on the types of positions affected by the layoffs. But they do appear to be connected to the company’s broader restructuring plans. 

“Novo regularly evaluates its organization to ensure we are positioned to meet evolving market dynamics and patient needs,” a Novo spokesperson told Fierce, confirming the layoffs. 

As of September 2026 the company has undertaken a “redesign of our US sales organization to create a more streamlined commercial model while maintaining our focus on serving patients, supporting healthcare professionals, advancing our current portfolio and future pipeline and ultimately driving sustainable growth in the US,” the spokesperson said.   

“Decisions that affect employees are never taken lightly and we are treating impacted colleagues with respect and providing appropriate support throughout the transition,” the spokesperson added. 

Restructuring has been a cornerstone of the turnaround effort led by new CEO Mike Doustdar, a 30-year Novo vet tapped in mid-2025 to right the ship as the drugmaker lost ground to Eli Lilly. Just a month into his tenure, Doustdar announced plans to trim 9,000 jobs globally, 5,000 of which were planned for the company’s Danish home base.  

At a Capital Market’s Day in September, Doustdar shared that an additional 4,000 employees had since left the company, brining the total layoff count in his first year to 13,000. 

“These are not easy decisions for us, but they were necessary, ” the CEO said at the time, noting that the workforce cuts had allowed Novo to redirect funds to R&D and sharpening the company’s competitive edge in the GLP-1 market.

Doustdar’s approach appears to be working, most notably in the company’s stellar launch of the Wegovy pill, which continues to outpace Lilly’s Foundayo in the oral market. The company reported 4% sales growth in its third-quarter earnings, largely driven by tailwinds from the oral GLP-1 launch. 

On Novo’s third-quarter earnings call, Doustdar called the company’s financial position evidence of a “growth recovery phase.”

Doustdar’s revamp didn’t stop at workforce and strategy changes. The CEO also lead a company-wide rebrand this year homing in on new objectives like customer obsession, clarity and competitiveness, as well as refreshing the company’s long-time logo and dropping “Nordisk” from the monicker.